Full text is available at the source.
Abstract
The developed mRNA drug targeting HTRA1 shows potential to inhibit the malignant phenotype of pancreatic ductal adenocarcinoma (PDAC) cells.
- High-temperature requirement protein A1 (HTRA1) is found to be upregulated in PDAC and contributes to disease progression.
- Lipid nanoparticles (LNP) enhance the delivery and effectiveness of mRNA drugs targeting HTRA1 in tumor cells.
- The anti-HTRA1 mRNA effectively inhibits the malignant characteristics of PDAC cells in vitro.
- In mouse models, the mRNA drug may improve the tumor microenvironment by inhibiting the HIF-1 signaling pathway.
- The findings suggest that mRNA drugs based on LNP could provide new options for targeted therapy in PDAC.
Simplified